

**Minutes of the September 20, 2013  
Pharmacy & Therapeutics (P&T) Committee Meeting  
South Dakota Department of Social Services, Division of Medical Services**

**Members Present**

Mikel Holland, MD; Lenny Petrik, PharmD; Richard Holm, MD; Debra Farver, PharmD; Dana Darger, RPh; Michelle Baack, MD; Kelly Oehlke, PharmD; Timothy Soundy, MD; Bill Ladwig, RPh; James Engelbrecht, MD

**DSS staff present**

Mike Jockheck, RPh

**Administrative Business**

The P&T meeting was called to order by D. Darger at 1:04pm. The minutes of the June 28, 2013 meeting were presented. M. Baack made a motion to approve. D. Farver seconded the motion. The motion was approved unanimously.

**Prior Authorization Update and Statistics**

The Committee reviewed the prior authorization (PA) activity for July 2013. There were a total of 2,412 PA's processed in the month of July, with 99.92% of those requests responded to in less than eight hours. There were 1,875 (78%) requests received electronically and 537 (22%) requests received by fax.

**Analysis of the top 15 Therapeutic Classes**

The Committee reviewed the Top 15 Therapeutic Classes by total cost of claims from 4/1/2013 – 6/30/2013. The top five classes were antipsychotics, respiratory and CNS stimulants, amphetamines, central nervous system agents, misc., and corticosteroids (respiratory tract). The top 15 therapeutic classes make up 40.93% of total claims. The Committee also reviewed the top 25 drugs based on total claims cost and number of claims. The top 25 drugs by claims cost make up 10.99% of total claims. The Committee requested that tramadol utilization be presented at the December meeting.

**Opiates Review**

At the June 2013 meeting, the Committee reviewed opiate utilization. The topic was brought back with additional utilization reports. In June the Committee suggested that a letter be sent to the top 25 prescribers of opiates. M. Jockheck reported that the letter was mailed in August 2013. The Committee heard a presentation regarding the South Dakota Prescription Drug Monitoring Program (PDMP). Members of the South Dakota Board of Pharmacy present to discuss the PDMP were Randy Jones and Kari Shanard-Koenders. Douglas Heilman represented the South Dakota Attorney General's office. The Committee requested more information regarding the utilization of hydrocodone/APAP combinations. The Committee also inquired if DSS can check with the Board of Pharmacy to determine how many of the prescribers who received a letter have registered to use the PDMP.

**PPI Review**

The Committee reviewed the proton pump inhibitor utilization data. The topic was tabled.

**Diclegis Review**

M. Baack made a motion to approve the PA form as presented. The motion was seconded by L. Petrik. The motion passed unanimously. There was no public comment.

**Zolpidem Review**

The Committee reviewed the zolpidem PA form. J. Englebrecht expressed concern with the recommended PA. D. Darger made a motion to implement a one per day quantity limit on zolpidem products. The motion was seconded by K. Oehlke. The motion passed unanimously. There was no public comment.

**Diabetes Test Strip Review**

The Committee reviewed diabetes test strip utilization data. The topic was tabled. The Committee heard testimony from Rashelle Mason (Roche Diagnostics), Alan Kaska (Abbott Diabetes Care), and Sharon D'Agostino (Johnson & Johnson).

**Giazo Review**

The Committee reviewed utilization data for Giazo. The topic was tabled. There was no public comment.

**Delzicol Review**

The Committee reviewed utilization data for Delzicol. The topic was tabled. There was no public comment.

**Epinephrine Auto-Injection Devices Review**

The Committee reviewed utilization data for epinephrine auto-injectors. The Committee requested more information pertaining to what products are currently available in the market place and how those products compare. There was no public comment.

The next meeting is scheduled for December 6, 2013. M. Baack motioned to adjourn the P&T Committee meeting. B. Ladwig seconded the motion. The motion passed unanimously and the meeting was adjourned.